4.7 Review

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC

Journal

LANCET ONCOLOGY
Volume 13, Issue 2, Pages E58-E68

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(12)70040-2

Keywords

-

Categories

Funding

  1. Grunenthal
  2. Cephalon
  3. Novartis
  4. Pfizer
  5. Mundipharma
  6. Molteni Pharmaceuticals
  7. Nycomed
  8. Menarini
  9. Archimedes
  10. Prostrakan
  11. Molteni
  12. Archimedes Pharma Ltd
  13. Cephalon UK
  14. Napp Pharmaceuticals
  15. Dompe
  16. MEDA
  17. EU [037777]
  18. Floriani Foundation of Milan
  19. Italian Association for Cancer Research (AIRC) [IG 9347]

Ask authors/readers for more resources

Here we provide the updated version of the guidelines of the European Association for Palliative Care ( EAPC) on the use of opioids for the treatment of cancer pain. The update was undertaken by the European Palliative Care Research Collaborative. Previous EAPC guidelines were reviewed and compared with other currently available guidelines, and consensus recommendations were created by formal international expert panel. The content of the guidelines was defined according to several topics, each of which was assigned to collaborators who developed systematic literature reviews with a common methodology. The recommendations were developed by a writing committee that combined the evidence derived from the systematic reviews with the panellists' evaluations in a co-authored process, and were endorsed by the EAPC Board of Directors. The guidelines are presented as a list of 16 evidence-based recommendations developed according to the Grading of Recommendations Assessment, Development and Evaluation system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available